[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cryotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cryotherapy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,70,110,134,157,192],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100644873","effect-of-two-different-cryotherapy-irrigation-protocols-on-postoperative-endodontic-pain-100644873",false,"NCT07676409","Effect of Two Different Cryotherapy Irrigation Protocols on Postoperative Endodontic Pain","Effect of Two Intracanal Cryotherapy Irrigation Protocols on Postoperative Endodontic Pain in Patients With Symptomatic Irreversible Pulpitis and Apical Periodontitis in Mandibular Molars: A Randomized Clinical Trial.","NAOCL\u002FEDTA","Inclusion Criteria:\n\n1. Age between 20-40 years old.\n2. Systemically healthy patients (ASA I or II).\n3. Mature Mandibular molar teeth with :\n\n   * Preoperative sharp pain and symptomatic apical periodontitis marked on NRS scale by reading not less than 6.\n   * Absence or slight widening in the periodontal ligament (PDL).\n   * Vital response of pulp tissue to cold pulp tester and (ethyl chloride spray).\n   * Positive response to percussion test.\n4. Restorable teeth.\n5. Ability to complete the endodontic treatment in a single visit.\n6. Positive patient acceptance for participation in the trial. -----------------------------------------------------------------\n\nExclusion Criteria:\n\n1. Medically compromised patients (ASA III or IV)\n2. Patients who used NSAIDs in the 24 hours before treatment.\n3. Patients with two or more adjacent teeth requiring endodontic treatment.\n4. Pregnant women.\n5. Patients reporting bruxism or clenching.\n6. Teeth associated with :\n\n   * Acute periapical abscess and\u002For swelling.\n   * Greater than grade I mobility or pocket depth greater than 5mm.\n   * Non-restorable teeth.\n   * Immature Apex.\n7. Radiographic evidence of external or internal root resorption, vertical root fracture, perforation, calcification.","ALL","20 Years","40 Years",{"count":21,"type":22},45,"ESTIMATED","INTERVENTIONAL",[25],"NA","The aim of this study is to evaluate the effect of intracanal cryotreated (2-3°C) 2.5% sodium hypochlorite and Saline used throughout the procedure, compared with a room-temperature irrigation protocol with a final cryotreated saline flush or an entirely room temperature irrigation protocol, on postoperative pain in patients with symptomatic irreversible pulpitis and symptomatic apical periodontitis in mandibular molars.",[28],"Cryotherapy",[28,30,31],"Postoperative endodontic pain","irrigation","NOT_YET_RECRUITING","2026-06-24",{"date":35,"type":36},"2026-06-30","ACTUAL",{"date":38,"type":22},"2026-06-15",{"date":40,"type":22},"2027-07-15",{"name":42,"class":43},"Cairo University","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100633750","post-market-registry-of-transbronchial-cryo-assisted-rfa-during-routine-standard-bronchoscopic-tumor-stagng-and-resection-100633750","NCT07530744","Post-Market Registry of Transbronchial Cryo-assisted RFA During Routine Standard Bronchoscopic Tumor Stagng and Resection","Cronos","Inclusion Criteria:\n\n* Solitary nodule ≤ 2.5 cm\n* Candidate for diagnostic bronchoscopy \\& LN staging\n* Eligible for surgical resection\n* Histologically proven lung cancer\n* ≥20 mm margin to pleura\u002Fvessels\u002Fbronchi\n* Signed informed consent, age ≥18 y.\n\nExclusion Criteria:\n\n* Pregnancy\u002Fnursing\n* central tumours abutting vital structures\n* thoracic electronic implants\n* uncorrectable coagulopathy or platelets ≤50 × 10⁹\u002FL\n* severe uncontrolled comorbidities or infection; prior SBRT to zone\n* recent investigational therapy (\\\u003C30 d)\n* atelectasis\u002Fobstructive pneumonitis\u002Feffusion\u002Ffibrosis\n* investigator-determined risk.",{"count":52,"type":22},20,[25],"In order to secure the diagnosis of lung cancer, the investigator will perform a bronchoscopy in order to take tissue samples. These samples will be analyzed in the pathology. This is the routine standard. The aim of the study is to treat the lesion with a device that works both with cold and radiofrequency. The device is already in use for the treatment of lesions. The device allows direct treatment of the lesion during the routine bronchoscopy. As planned, the lesion will then be surgically removed. After the surgery the lesion will be analyzed in the pathology to show the effect of the use of the device. This additional treatment is safe and will support the treatment of the lesion. There are no additional steps or assessments for the participants to undergo.",[56,28,57],"NSCLC","RFA",[59],"Tumor Staging and Resection","2026-04-07",{"date":62,"type":36},"2026-04-15",{"date":64,"type":22},"2026-05",{"date":66,"type":22},"2028-10",{"name":68,"class":43},"Elisabethinen Hospital",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":90,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":109},"100588282","intracoronary-cryotherapy-effect-on-stabilization-of-vulnerable-plaque-in-patients-with-stable-angina-or-acs---a-traditional-feasibility-study-100588282","NCT06939374","Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With Stable Angina or ACS - A Traditional Feasibility Study","Clinical Investigation of the Efficacy and Safety of Intracoronary Cryotherapy Using the CryoTherapy System (CTS) for High-risk Plaque in Patients With Stable Angina or Acute Coronary Syndrome.","ICECAP","Inclusion Criteria:\n\n* 1\\) Subject is at least 18 years old. 2) Subject has acute cardiac pain\u002Fangina consistent with stable angina or acute coronary syndrome eligible for coronary angiography meeting one of the following criteria:\n\n  1. Non-ST-segment elevation myocardial infarction (NSTEMI) with rise\u002Ffall of cardiac enzymes (troponin I or T) with at least one value above the 99th percentile of the upper reference limit requiring PCI within 72 hours from diagnosis\n  2. Unstable angina\n  3. ST-segment elevation myocardial infarction (STEMI) 3) Successful PCI (defined as diameter stenosis less than 30% and TIMI 3 flow on final angiography without procedural complication) of the culprit lesion.\n\nNOTE: subjects with unstable angina, for whom the culprit lesion as assessed by investigator does not require PCI currently or within the next 6 months (subject treated with optimal medical treatment) can be enrolled in the study.\n\n4\\) Subject has at least one high-risk plaque meeting the criteria below:\n\n1. Located in a non-culprit vessel,\n2. High-risk plaque lesion on CCTA and at least one of the following features:\n\n   1. Presence of low-attenuation plaque (HU\\\u003C50) and\u002For\n   2. Positive remodelling (remodelling index \\>1.1) and\u002For\n   3. Napkin ring sign and\u002For\n   4. Plaque burden ≥70%\n3. Lesion length ≤ 20 mm.\n4. Diameter stenosis on invasive angiography between 30% and 70% on coronary angiogram or negative physiology assessment (FFR\\>0.80 or NHPR\\>0.89).\n5. Reference vessel diameter (RVD) \\\u003C 3.75 mm and \\> 2.50 mm in diameter\n6. Investigator considers that lesions are accessible.\n7. If more than two suitable lesions available, investigator will select the most appropriate lesion for cryotherapy treatment.\n\n   5\\) maxLCBI4mm in the lesion \\> 324.7 6) Subject is able to provide consent and has signed and dated the informed consent form.\n\n   Exclusion Criteria:\n   * 1\\) Subject is hemodynamically unstable (cardiogenic shock, hypotension needing inotropes, hypoxia needing intubation, refractory ventricular arrhythmias, and IABP).\n\n     2\\) Subject has ongoing ST-segment elevation myocardial infarction. 3) Subject had a procedural complication during the ACS PCI procedure. 4) Subject has history of Coronary Artery Bypass Graft (CABG) or planned CABG within 12 months after the index procedure.\n\n     5\\) Subject has known reduced Left Ventricular Ejection Fraction \\\u003C 30%. 6) Subject has known severe valvular heart disease. 7) Subject has known severe renal insufficiency (eGFR \\\u003C30 ml\u002Fmin\u002F1.72 m2). 8) Subject has any life-threatening conditions or medical comorbidity resulting in life expectancy \\\u003C 12 months.\n\n     9\\) Subject is currently participating in another clinical investigation that has not yet reached its primary endpoint.\n\n     10\\) Subject has severe peripheral vascular disease impeding femoral artery access.\n\n     11\\) Subject is pregnant or lactating, or NOT surgically sterile (tubal ligation or hysterectomy) or NOT postmenopausal for at least 6 months or is a female with childbearing potential without effective contraception (pill, patch, ring, diaphragm, implant and intrauterine device).\n\n   Angiographic exclusion criteria:\n   1. Visible distal embolization\u002Fno-reflow following culprit lesions PCI.\n   2. Left main coronary artery disease (visual diameter stenosis \\> 50%).\n   3. Stent thrombosis\u002Frestenosis as a culprit lesion.\n   4. CTS lesion involving a bifurcation (defined as lesions involving side branches \\>2.0 mm).\n   5. Angiographic or CCTA evidence of severe calcification and\u002For marked tortuosity of the index vessel and\u002For lesion.\n   6. Thrombotic lesions.\n   7. Ostial lesions.","18 Years",{"count":80,"type":22},30,[25],"ICECAP is a multi-centre, prospective, single-arm, interventional, traditional feasibility clinical investigation to evaluate the efficacy and safety of intra-coronary cryotherapy on vulnerable or high-risk plaque (HRP), using the CryoTherapy System (CTS). The study aims to enroll 25 patients with symptomatic coronary artery disease, successfully treated for their culprit lesion and with presence of at least one HRP lesion in another vessel. Eligible patients will undergo cryotherapy during a planned procedure. Near-infrared spectrometry (NIRS and Optical Coherence Tomography imaging will be used during baseline procedure, and during a 9 months follow visit. The primary endpoint is reduction of plaque burden measured as 30% reduction in maxLCBI4mm as measured by NIRS at 9 months post procedure.",[84,85,86,28,87,88,89],"Coronary Arterial Disease (CAD)","Plaque","Vulnerable Plaque","Cryotherapy Effect","Coronary Balloon","Atherosclerosis Coronary Artery With Angina Pectoris",[91,92,93,94,95,96,97],"Medical device","traditional feasibility","Single Group","Device Feasibility","Multi-Center","Prospective","Interventional","RECRUITING","2026-03-31",{"date":101,"type":36},"2026-04-06",{"date":103,"type":36},"2025-03-01",{"date":105,"type":22},"2027-06-30",{"name":107,"class":108},"Cryotherapeutics SA","INDUSTRY",3,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":117,"sex":17,"minAge":78,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100623972","effect-of-cryotherapy-on-anesthetic-success-and-pain-in-irreversible-pulpitis-100623972","NCT07403578","Effect of Cryotherapy on Anesthetic Success and Pain in Irreversible Pulpitis","Effect Of Cryotherapy On Anesthetıc Success And Intraoperatıve Paın In Mandıbular Premolars Wıth Irreversıble Pulpıtıs: A Prospectıve Randomızed Clınıcal Trıal","Inclusion Criteria:\n\n* Systemically healthy patients classified as ASA I or II, aged between 18 and 60 years,\n* Presence of a restorable mandibular premolar tooth diagnosed with symptomatic irreversible pulpitis,\n* History of spontaneous pain or lingering pain elicited by thermal stimuli,\n* Positive response with lingering pain to cold testing (Endo Ice; Coltene, Altstätten, Switzerland),\n* Positive response at low current levels to electric pulp testing (Parkell Inc., USA),\n* Teeth with closed apex and no radiographic evidence of periapical pathology (intact periodontal ligament space and absence of periapical radiolucency),\n* Patients presenting with moderate or severe preoperative pain, as assessed using the visual analogue scale (VAS).\n\nExclusion Criteria:\n\n* Patients who had taken analgesic, anti-inflammatory, or opioid medication within the last 12 hours before treatment,\n* Patients with systemic conditions that may affect pain perception, inflammatory response, or healing,\n* History of antibiotic use within the previous month or requirement for antibiotic prophylaxis,\n* Teeth presenting with clinical or radiographic signs of pulp necrosis or apical periodontitis (Pain on percussion or palpation, presence of sinus tract or swelling, presence of periapical radiolucency),\n* Teeth with root resorption, immature apices, severe coronal destruction preventing proper isolation, or calcified canals,\n* Teeth that had undergone previous endodontic treatment, including pulpotomy or root canal filling,\n* Patients with neurological or psychiatric conditions that could interfere with pain perception or accurate pain reporting,\n* Inability to achieve adequate isolation with a rubberdam.",true,"60 Years",{"count":120,"type":22},100,[25],"This prospective randomized clinical trial aimed to evaluate the effects of different anesthesia protocols on anesthetic success and intraoperative pain during root canal treatment of mandibular premolars diagnosed with symptomatic irreversible pulpitis. A total of 100 systemically healthy patients were randomly allocated into four groups: infiltration anesthesia alone, inferior alveolar nerve block (IANB) alone, infiltration anesthesia combined with cryotherapy, and IANB combined with cryotherapy. Cryotherapy was applied intraorally for 5 minutes immediately after anesthetic administration.\n\nThe effectiveness of anesthesia was confirmed using electric pulp testing and cold testing prior to treatment. Root canal therapy was completed in a single visit by a calibrated operator. Intraoperative pain was assessed during access cavity preparation using a visual analogue scale (VAS). Anesthetic success was defined as the presence of no or mild pain, whereas moderate or severe pain indicated anesthetic failure and required supplemental anesthesia.\n\nThe primary objective of the study was to determine whether the adjunctive use of cryotherapy improves anesthetic success and reduces intraoperative pain in mandibular premolars with symptomatic irreversible pulpitis. The null hypothesis was that no significant differences would be observed among the study groups in terms of anesthetic success or intraoperative pain intensity.",[124,28],"Irreversible Pulpitis","2026-02-10",{"date":127,"type":36},"2026-02-11",{"date":129,"type":22},"2026-01-30",{"date":131,"type":22},"2026-12-30",{"name":133,"class":43},"TC Erciyes University",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":69},"100621139","monocentric-randomised-controlled-trial-assessing-cryocompression-following-total-knee-replacement-100621139","NCT07366736","Monocentric Randomised Controlled Trial Assessing Cryocompression Following Total Knee Replacement","CryoTKR","Inclusion Criteria:\n\n* aged ≥18 years\n* scheduled for primary TKR\n* BMI \\\u003C40 kg\u002Fm2\n* who signed the informed consent and are willing to comply with the protocol requirements based on the investigator's judgment\n* affiliated with a social security scheme\n* with an ability to answer questionnaires and to communicate freely in French.\n\nExclusion Criteria:\n\n* underwent revision TKR\n* underwent bilateral TKR\n* who cannot comply with the protocol requirements based on the investigator's judgment\n* that are pregnant or breastfeeding\n* with protected status under articles L1121-6, LL121-8 and L1122-2 of the French Public Health Code",{"count":142,"type":22},138,[25],"Immediately following surgery, icepacks are commonly used to decrease inflammation and reduce pain and have demonstrated to decrease post-operative opioid consumption. New cryocompression devices have been introduced as a non-invasive and non-pharmacological modality used to manage acute inflammation and pain, demonstrating benefits in the post- operative setting promoting vasoconstriction, reducing blood flow and inflammation. The addition of compression may further decrease inflammation and pain, revealed in studies on anterior cruciate ligament reconstruction, total hip replacement, and lumbar fusion.\n\nRecently, an RCT was published by Marinova et al. that compared cryocompression to icepacks following TKR in terms of pain on VAS, range of motion (ROM), knee circumference, and opioid consumption, but only found significant differences in extension ROM at day 1 and at 2 weeks. Due to the small sample size of Marinova et al. and high rates of losses to follow-up due to COVID-19, there remains doubt on the efficacy of cryocompression for TKR. Furthermore, cryocompression require additional investment in terms of cost to acquire the devices, and in time to train the hospital staff, and the devices may not be available for every patient. Finally, the authors are unsure how cryocompression affects wound healing in the short- and long-term.\n\nThe hypothesis was that both cryocompression and regular icepacks would grant equivalent pain on numeric rating scale at 48 hours postoperatively.",[146,28,147],"Total Knee Anthroplasty","Compression","2026-01-16",{"date":150,"type":36},"2026-01-26",{"date":152,"type":36},"2025-10-27",{"date":154,"type":22},"2027-07-27",{"name":156,"class":43},"Clinique des Cèdres",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":117,"sex":17,"minAge":78,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":23,"phases":167,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":69},"100609196","acute-cryotherapy-on-musculoskeletal-function-and-biomarkers-100609196","NCT07211412","Acute Cryotherapy on Musculoskeletal Function and Biomarkers","Effects of Acute Cryotherapy on Musculoskeletal Function and Biomarkers for Inflammation, Oxidative Stress, and Muscle Damage","Inclusion Criteria:\n\n* apparently healthy\n* normotensive\n* non-smokers (all tobacco products including e-cigarettes)\n\nExclusion Criteria:\n\n* Cardiovascular diseases (including hypertension)\n* pregnancy\n* any musculoskeletal injury 6 months prior the study","30 Years",{"count":166,"type":22},60,[25],"In 2020, Dubois and Esculier proposed a paradigm shift in the acute management of musculoskeletal injuries, advocating for the transition from the traditional PRICE protocol- Protect, Rest, Ice, Compression, Elevation-to the more holistic PEACE \\& LOVE framework. This updated model emphasizes Protection, Elevation, Avoiding anti-inflammatories, Compression, and Education, followed by Load, Optimism, Vascularization, and Exercise. Notably, the PEACE \\& LOVE approach omits the use of ice, a decision that has sparked considerable debate. While the rationale centers on avoiding interference with the natural inflammatory and regenerative processes, this omission stands in contrast to a substantial body of animal research suggesting that cryotherapy can mitigate secondary tissue injury by reducing inflammation and metabolic activity. Despite its widespread clinical use, human studies have yet to provide conclusive evidence supporting or refuting the efficacy of cryotherapy in acute injury management, leaving clinicians to navigate between tradition, emerging evidence, and evolving philosophies of care. Even though it is important to consider natural inflammation for a better regenerative process, animal models have shown that the original injury can elicit oxidative stress, which will enhance cellular damage (secondary damage) and inflammation. Clinically, it is unknown if this secondary damage would increase functional impairment.\n\nTherefore, this proposal will determine if cryotherapy can decrease secondary damage, after exercise-induced muscle damage, and if this decrease is associated to lower inflammation, oxidative stress and functional impairments.",[170,28],"Exercise Induced Muscle Damage",[172,28,173,174,175,176,177,178,179,180,181,182],"Exercise induced muscle damage","Cold-pack","Ice-pack","Eccentric exercise","Creatine kinase","c-reactive protein","interlukin-6","8-isoprostane","Range of motion","Maximal Voluntary Isometric Contraction","Pain","2025-10-01",{"date":185,"type":36},"2025-10-08",{"date":187,"type":22},"2025-10-15",{"date":189,"type":22},"2026-05-15",{"name":191,"class":43},"University of Texas, El Paso",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":23,"phases":201,"briefSummary":202,"conditions":203,"keywords":206,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":69},"100563636","focal-cryoballoon-ablation-for-malignant-dysphagia-100563636","NCT06618742","Focal Cryoballoon Ablation for Malignant Dysphagia","Focal Cryoballoon Ablation for Dysphagia Palliation in Patients with Advanced Esophageal Cancer","DYS-CBAS","Inclusion Criteria:\n\n* Age \\>18 years at time of consent\n* Histopathologically-confirmed esophageal \u002F gastroesophageal cancer\n* Patients in the palliative setting (with or without (future) systemic chemotherapy)\n* Dysphagia defined as a score of ≥2 (able to swallow only semi-solids)\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Alternative etiology for dysphagia\n* Inability to pass the ultraslim endoscope\n* Severe medical comorbidities precluding endoscopy\n* Uncorrected coagulopathy\n* Prior distal esophagectomy\n* Previous esophageal varices\n* Expected survival \\<6 weeks\n* Prior radiotherapy for esophageal cancer\n* T4b esophageal cancer\n* Incapacitated subjects\n* Pregnant or breastfeeding",{"count":52,"type":22},[25],"Rationale:\n\nDysphagia is commonly encountered in patients with esophageal carcinoma who are no candidates for treatment with curative intent. It often has a considerable impact on quality of life and can cause malnourishment. Current palliative treatments mainly include esophageal stenting and radiotherapy, but these can be associated with substantial drawbacks such as a high rate of adverse events, fatigue or an untimely\u002F temporary symptom improvement. Recent studies showed promising results for the use of spray cryotherapy as palliation for dysphagia. Moreover, there are suggestions that cryotherapy has a positive effect on the host's anti-tumor response. However, no data exists on the feasibility, efficacy and safety for cryoballoon therapy in the esophagus. Secondly, cryo-immunologic data in patients with EC is lacking.\n\nObjective:\n\n1. To evaluate the feasibility of cryoballoon ablation in patients with esophageal carcinoma and symptoms of dysphagia. Additionally, efficacy and safety will be assessed.\n2. To evaluate the effect of cryoballoon ablation on host's anti-tumor response. Study design: Pilot study, Multi-center Prospective Uncontrolled Intervention\n\nStudy Study population: Adult patients (≥18 years) with dysphagia due to incurable esophageal carcinoma Intervention (if applicable): Focal cryoballoon ablation of visible tumor during an upper endoscopy. Cryoballoon ablation will be performed for two cycles of 12 seconds. In total, patients will undergo 3 treatment sessions (range 1-3) with an interval of 1-3 weeks based onthe severity of symptoms reported by the patient.\n\nMain study parameters\u002Fendpoints:\n\n* \\- Feasibility of cryoballoon ablation defined as technical success of the procedure\n\n  * Safety based on incidence of procedure-related serious adverse events\n  * Efficacy defined as success rates two weeks after the last cryoablation treatment based on patient reported symptom improvement, and objective evaluation of the esophageal lumen that is free from tumor\n* Host's anti-tumor response after cryoballoon ablation based on sequential esophageal tumor biopsies and peripheral blood samples",[204,205,28],"Dysphagia","Esophageal Cancer",[207],"cryoballoon ablation","2024-09-27",{"date":210,"type":36},"2024-10-01",{"date":212,"type":36},"2024-06-24",{"date":214,"type":22},"2025-12-31",{"name":216,"class":43},"Laura Boer"]